Does the bile acid receptor TGR5 play a role in Kupffer cell response during Alcoholic Liver Disease?
EASL LiverTree™, Madeleine Spatz, 207339
Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition 
EASL LiverTree™, Michal Safran, 207342
Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis
EASL LiverTree™, Christelle Devisme, 207358
Autophagy-related liver enzymes in chronic liver disease
EASL LiverTree™, Dimitrios Samonakis, 207359
PREVALENCE AND PREDICTIVE FACTORS OF HEPATIC NODULES IN PATIENTS WITH FONTAN SURGERY: THE VALDIG FONLIVER STUDY
EASL LiverTree™, Enrique Rodríguez-Santiago, 207374
The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease
EASL LiverTree™, René van Aerts, 207375
The PR interval in the fetal electrocardiogram is significantly prolonged in severe Intrahepatic Cholestasis of Pregnancy and potentially normalised by UDCA therapy
EASL LiverTree™, Tharni Vasavan, 207376
DIFFERENTIALDIAGNOSTICS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN OF EARLY AGE 
EASL LiverTree™, Galina Volynets, 207377
Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study. 
EASL LiverTree™, Rodrigo Starosta, 207393
Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis
EASL LiverTree™, Teresa Dias, 207394
Evaluation of the New criteria in the diagnosis of cystic fibrosis liver disease
EASL LiverTree™, Iliana Mani, 207395
Enhanced Liver Fibrosis (ELF) Test predicts liver-related outcomes in postmenopausal women with risk factors in the community
EASL LiverTree™, Paul Trembling, 207411
Correlation between controlled attenuationparameter assessed with Fibroscan and steatosis percent objectively quantifiedfrom the entire liver biopsy specimen using a computer analysis tool. Preliminary results.
EASL LiverTree™, Monica Platon Lupsor, 207412
Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation
EASL LiverTree™, Seong Hee Kang, 207413
Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter
EASL LiverTree™, Valentin Blank, 207414
Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis
EASL LiverTree™, Tomi Jun, 207428
Distribution and changes of FIB-4 index in normal health checkup examinees
EASL LiverTree™, Shuhei Hige, 207430
Which is the chance for type 2 diabetes patients to develop severe liver disease?
EASL LiverTree™, Ioan Sporea, 207431
Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values.
EASL LiverTree™, Emma Robinson, 207432
Nrf2 pathway plays an important role in the development of hepatocellular carcinoma:  the gene expression signature of Nrf2 observed in a rat hepatocarcinogenesis model
EASL LiverTree™, Carlos David López, 207450
ADAR-mediated A-to-I RNA Editing in Human Hepatocelluar Carcinoma
EASL LiverTree™, Guangqi Song, 207451
Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma
EASL LiverTree™, Paola Alejandra Romecin Duran, 207452
In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma
EASL LiverTree™, Antonio Saviano, 207453
Interventional gene targeting of cell cycle regulators identifies Cyclin E1 as a suitable target for attenuating hepatocellular carcinoma progression
EASL LiverTree™, Roland Sonnatg, 207467
Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: the Blueprint-HCC study.
EASL LiverTree™, David James Pinato, 207468
Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma
EASL LiverTree™, Yu Rim Lee, 207470
OBETICHOLIC ACID, A FXR AGONST, INHIBITS THE CANCEROGENIC POTENTIAL OF PRIMARY HUMAN CHOLANGIOCARCINOMA (CCA) CELLS CULTURES
EASL LiverTree™, Sabina Di Matteo, 207487
Sensitization of cholangiocarcinoma to chemotherapy by SOX17-induced down-regulation of drug export pumps ABCC3 and AGCG2
EASL LiverTree™, Rocio Macias, 207488
Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells
EASL LiverTree™, STEFANIA MANTOVANI, 207489
Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening
EASL LiverTree™, Charlotte Ng, 207490
Impact of Trp53  on tumor heterogeneity in the background of liver fibrosis
EASL LiverTree™, Umesh Tharehalli Mathada, 207504
Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile.
EASL LiverTree™, Tutusaus Anna, 207505
MALDI IMAGING OF HEPATOCHOLANGIOCARCINOMAS: A CLUE TO TACKLE TUMOR HETEROGENEITY. PRELIMINARY RESULTS
EASL LiverTree™, Elia Gigante, 207506
Aspecific ECM composition regulates Smad dependent - TGFbeta1-induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds
EASL LiverTree™, Krista Rombouts, 207508
Outcomes of pregnancy in women with cirrhosis - a national, population-based cohort study
EASL LiverTree™, Hannes Hagström, 207522
Prevalence and resistance rates of infections with enterococci in patients with cirrhosis
EASL LiverTree™, Theresa Bucsics, 207523
The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study
EASL LiverTree™, Cornelius Engelmann, 207526
The Cost-Effectiveness of Albumin in the Treatment of Decompensated Cirrhosis in Italy, Spain and Germany 
EASL LiverTree™, Paolo Caraceni, 207539
The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis
EASL LiverTree™, Tammo Lambert Tergast, 207540
Antibiotic-Associated Disruption of Microbial Composition and Functionality is Restored after Fecal Transplant in Cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 207541
Beta-Blocker use in Cirrhosis is Independently Associated with Minimal Hepatic Encephalopathy
EASL LiverTree™, Jasmohan S Bajaj, 207542
Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis 
EASL LiverTree™, Irina Girleanu, 207555
Decreased Model for End-Stage Liver Disease (MELD) score after antiviral treatment predicts reduced risk of mortality and hepatic events in chronic hepatitis B related cirrhosis - a study of 1,729 subjects
EASL LiverTree™, Grace LH Wong, 207556
Propranolol Treatment Associated with Better Survival and Reduced Sepsis in Cirrhotic Patients with Hepatic Encephalopathy
EASL LiverTree™, Pei Chang Lee, 207557
Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis
EASL LiverTree™, ThucNhi Dang, 207558
Uncontrolled diabetes increases all causes of mortality and particularly cardiovascular death in patients with cirrhosis
EASL LiverTree™, Maria de Fatima Higuera de la Tijera, 207573
TIPS placement improves sarcopenia and modifies fat distribution: a monocentric retrospective study 
EASL LiverTree™, Florent Artru, 207574
Increasing Burden of Hepatic Encephalopathy among Hospitalized Adults, With Significantly Higher Risk of In-Hospital Mortality in African Americans: An Analysis of the 2007-2013 Nationwide Inpatient Sample
EASL LiverTree™, Grishma Hirode, 207575
Health care costs are double for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC) who progress to end-stage liver disease (ESLD)
EASL LiverTree™, Rohit Loomba, 207576
Clinical frailty scale as a novel tool predicts unplanned hospitalisation and/or death in outpatients with cirrhosis.
EASL LiverTree™, ANIRUDDHA PRATAP SINGH, 207591
RELATIONSHIP BETWEEN VISCERAL FAT AND PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS
EASL LiverTree™, Marta Hernandez Conde, 207592
Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension
EASL LiverTree™, Peter Lykke Eriksen, 207593
Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience
EASL LiverTree™, Nikolaus Pfisterer, 207594
Efficacy of Liver Stiffness Measurement and Platelet Count in Screening for High Grade Varies in Patients with Cirrhosis.
EASL LiverTree™, ashish agarwal, 207608
Tolerability and Kinetics of SYNB1020 in a Phase 1, First-in-Human, Healthy Adult Volunteer Study
EASL LiverTree™, Marja Puurunen, 207610
Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy?
EASL LiverTree™, Signe Wiese, 207611
The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis
EASL LiverTree™, Signe Wiese, 207612
Repeated episodes of acute kidney injury (AKI) on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes
EASL LiverTree™, Shuet Fong Neong, 207626
Eradication of hepatitis C virus (HCV) in patients with decompensated cirrhosis does not improve the management of ascites after one year of follow-up.
EASL LiverTree™, Adrià Juanola Mayos, 207627
Gender differences regarding sarcopenia development in  chronic liver disease
EASL LiverTree™, Atsushi Hiraoka, 207628
Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI
EASL LiverTree™, Maria C. Speranta Iacob, 207629
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
EASL LiverTree™, Hiroaki Takaya, 207645
Sustained Long-term Improvement in Clinical and Cognitive Outcomes after Fecal Microbiota Transplantation in Cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 207646
High Mortality Rate in HBV-related Cirrhosis Patients with HEV Superinfection
EASL LiverTree™, Tai-Chung Tseng, 207647
DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation
EASL LiverTree™, Fleur Chapus, 207663
Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes
EASL LiverTree™, Philippa Matthews, 207664
LTPprodrug technology offers new generation nucleotide antiviral agents 
EASL LiverTree™, Lin Zhi, 207665
In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B
EASL LiverTree™, Lu Gao, 207680
HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells
EASL LiverTree™, Yasuhiro Asahina, 207681
Post transcriptional regulation of Hepatitis B virus in a prospective cohort of chronically infected patients
EASL LiverTree™, Aurélie Schnuriger, 207682
Biogenesis and Function of Intracellular Hepatitis B e Antigen
EASL LiverTree™, Bidisha Mitra, 207695
Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate virus replication
EASL LiverTree™, Wenshi Wang, 207697
Pro-fibrogenic mediator Osteopontin is intimately involved in Chronic Hepatitis B and promotes cccDNA production
EASL LiverTree™, Sandra Phillips, 207698
Whole Genome Viral Sequencing Reveals Subgenotype Specific Dynamics of Antiviral Treatment Response in HBeAg Positive and Treatment Naive Chronic Hepatitis B Patients
EASL LiverTree™, Ondrej Podlaha, 207699
Prevalence, Pathogenesis and Cross-species Transmission of A Novel Hepatitis E Virus from Bactrian Camels
EASL LiverTree™, Lin Wang, 207714
HCV induced-miR-21 activation triggers lipid accumulation and promotes viral replication
EASL LiverTree™, Sophie Clément, 207716
Hepatitis E virus replication and interferonresponse in human placental-derived cells
EASL LiverTree™, Patrick Behrendt, 207717
Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes
EASL LiverTree™, Upkar Gill, 207733
HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load
EASL LiverTree™, Upkar Gill, 207734
Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes
EASL LiverTree™, Katrin Manske, 207735
The RNA genome of hepatitis E virus robustly triggers antiviral interferon response
EASL LiverTree™, Wenshi Wang, 207736
Association of PD1 and TIM3 Polymorphisms with HBV Susceptibility
EASL LiverTree™, chunhong huang, 207752
Preclinical mechanistic and efficacy evaluation of a novel small molecule TLR7 agonist RO7020531 for the treatment of chronic hepatitis B
EASL LiverTree™, Lu Gao, 207753
A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication
EASL LiverTree™, Qin Wang, 207754
Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States 
EASL LiverTree™, George Cholankeril, 207755
The Bile Acid Biome and Its Relationship to the Development and Severity of Alcoholic Hepatitis
EASL LiverTree™, Puneet Puri, 207769
Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease
EASL LiverTree™, Marta Guerrero-Misas, 207770
Hepatoprotective Biomarkers, Amphiregulin and Soluble Fas, IncreaseDuring ELAD Treatment in Alcoholic Hepatitis Subjects
EASL LiverTree™, Jason Lapetoda, 207771
The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death
EASL LiverTree™, Ulrich Bang, 207772
Stage-specific Benefits of Treatment Associated Fibrosis Regression in Patients with NASH: A Markov Modeling Approach
EASL LiverTree™, Jagpreet Chhatwal, 207787
Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD
EASL LiverTree™, Alexandra Feldman, 207789
Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort
EASL LiverTree™, Naim Alkhouri, 207790
Associations between Sarcopenia and Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in the United States
EASL LiverTree™, Karn Wijarnpreecha, 207804
The Platelet Count is Declining in American Adults in Parallel with an Increase in Risk Factors for Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Amandeep Singh, 207805
The relationship between NAFLD and breast cancer: High prevalence and poor prognosis.
EASL LiverTree™, Young-Sun Lee, 207807
Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease
EASL LiverTree™, Thomas Karlas, 207808
The triglycerides and glucose (TyG) index : a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients?
EASL LiverTree™, Stephanie Faure, 207821
Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars
EASL LiverTree™, Panu Luukkonen, 207822
Low-moderate alcohol use is associated with a  lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US:  Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
EASL LiverTree™, Aynur Unalp-Arida, 207823
Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study
EASL LiverTree™, Veeral Ajmera, 207824

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings